Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Idraparinux sodium

Base Information
  • Chemical Name:Idraparinux sodium
  • CAS No.:149920-56-9
  • Molecular Formula:C38H64 O49 S7 . 9 Na
  • Molecular Weight:1727.1768
  • Hs Code.:
  • UNII:H84IXP29FN
  • Wikipedia:Idraparinux
  • Wikidata:Q3147909
  • NCI Thesaurus Code:C170051
  • Mol file:149920-56-9.mol
Idraparinux sodium

Synonyms:idraparinux;idraparinux sodium;ORG 34006;ORG-34006;SANORG 34006;SANORG-34006;SR 34006;SR-34006;SR34006

Suppliers and Price of Idraparinux sodium
Supply Marketing:
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
Total 4 raw suppliers
Chemical Property of Idraparinux sodium
Chemical Property:
  • Boiling Point:°Cat760mmHg 
  • Flash Point:°C 
  • PSA:760.84000 
  • Density:g/cm3 
  • LogP:-5.21950 
  • Hydrogen Bond Donor Count:0
  • Hydrogen Bond Acceptor Count:49
  • Rotatable Bond Count:26
  • Exact Mass:1725.8936149
  • Heavy Atom Count:103
  • Complexity:3190
Purity/Quality:

98% *data from raw suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:
Useful:
  • Canonical SMILES:COC1C(OC(C(C1OC)OC)OC2C(C(C(OC2C(=O)[O-])OC3C(OC(C(C3OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC4C(C(C(OC4C(=O)[O-])OC5C(OC(C(C5OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
  • Isomeric SMILES:CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OC)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)[O-])O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)[O-])O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
  • Recent ClinicalTrials:Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs
  • Recent EU Clinical Trials:International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity.
  • Uses Antithrombotic, indirect, selective, synthetic factor Xa inhibitor.
Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 149920-56-9